Demant released a trading update on Oct. 9, 2026, citing strong US sales of its newly launched Oticon Zeal product, and announced a DKK 3 billion share buyback program through 2027. Shares rose 6% on the day.
Demant’s strong product pipeline, led by the global rollout of Oticon Zeal in 2026, will likely result in above-market growth in the next few years.
Demant has underperformed Sonova over the last two years in hearing aids. Sonova was the first to introduce real-time AI implementation, taking share from Demant.
|
Metric
|
DEMANT
|
SOON
|
|---|---|---|
Price/Earnings (Normalized) | 29.54 | 28.08 |
Price/Book Value | 6.78 | 6.40 |
Price/Sales | 3.09 | 4.65 |
Price/Cash Flow | 17.83 | 21.73 |
|
Metric
|
DEMANT
|
SOON
|
|---|---|---|
Quick Ratio | 0.54 | 1.17 |
Current Ratio | 0.82 | 1.75 |
Interest Coverage | 6.70 | 23.14 |
|
Metric
|
DEMANT
|
SOON
|
|---|---|---|
Return on Assets (Normalized) | 6.76% | 11.07% |
Return on Equity (Normalized) | 24.80% | 24.50% |
Return on Invested Capital (Normalized) | 9.75% | 16.97% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|%#&Kv% | LOCK|glVM | $178B | |||
| Medtronic PLC
MDT
| LOCK|Z!>^m> | LOCK|$J#k | $120B | |||
| Stryker Corp
SYK
| LOCK|K@<c#JZ | LOCK|@tH | $116B | |||
| Boston Scientific Corp
BSX
| LOCK|mxm&@Y< | LOCK|<SpV< | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|x^&&c#ts | LOCK|$$^t | $52B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|YfpHb$S | LOCK|NR? | $32B | |||
| DexCom Inc
DXCM
| LOCK|#RJfrq@b | LOCK|m&<^? | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|#rK | LOCK|TK | $26B | |||
| Steris PLC
STE
| LOCK|!PR>&p | LOCK|Z$@w | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|&ysH$vsz | LOCK|Q^y | $18B |
United States